To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 09, 2018

Today's Rundown

Featured Story

Buoyed by insiders, Flagship’s Evelo hits midpoint of IPO range

Evelo Biosciences has priced its IPO at the midpoint of the range, giving it a gross haul of $85 million. The Flagship Ventures-backed microbiome startup is getting the IPO away with the strong support of its existing investors, who will contribute $40 million of the total haul.

Top Stories

Genentech forms $1B discovery collaboration with soil-prospector Lodo Therapeutics

Genentech signed up for a broad, open-ended drug discovery collaboration with Lodo Therapeutics that could be worth nearly $1 billion, focused on deriving unique, natural products from the microbial DNA found in soil.

Novartis, Durect renegotiate $293M painkiller deal after phase 3 failure

Novartis renegotiated its $293 million deal to commercialize Durect’s Posimir postoperative painkiller, cutting its milestone payments following the failure of a phase 3 trial reported last October.

[Sponsored] Optimize Human Gene Transfer Trials: Create Efficiencies with Coordinated IRB & IBC Review

Avoid delays in gene transfer trial start-up with tips from leading IRB and IBC experts.

Escient Pharma grabs $40M to push orphan GPCR drugs into the clinic

Escient Pharmaceuticals launched with $40 million to develop GPCR-targeted drugs for a wide range of indications, with an initial focus on neuro-immuno-inflammatory and autoreactive diseases. 

Abcam ends pursuit of £270M Horizon Discovery buyout

Abcam has ended its pursuit of Horizon Discovery one week after going public about its attempt to buy the gene editing specialist. 

Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug

Novartis’ FLT3 inhibitor Rydapt was a much-welcomed addition to the armamentarium against acute myeloid leukemia when it was approved last year. Now, Daiichi Sankyo has data that could allow it to file its new-generation rival for approval.

New engineering method could overcome barriers in diabetes cell therapy

Scientists in the U.S. and Japan devised a new tissue engineering method to tackle blood supply problems in pancreatic cell transplantation.

Drugmakers are down with AI, experts agree. They're just not sure what to use it for

Pharma’s plenty enthusiastic when it comes to artificial intelligence. The thing is, companies aren’t exactly sure yet how they should be using it.

Resources

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] 2018 Life Sciences Trends

What are the biggest trends in life sciences this year?

[Whitepaper] Choosing the Best Steriles Dosage Form for Your Phase I Clinical Supply Needs

There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development.

[Whitepaper] The Future of Life Sciences Events Management

Explore a new model for events management, and learn how to deliver more value.

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights.

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams.

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Regulatory Transformation at UCB

UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off.

[Whitepaper] Five Tracking Spreadsheets it’s Time for Regulatory to Retire

Find out how to eliminate regulatory’s tracking spreadsheets for good.

[Whitepaper] A Simpler Approach to RBM in Clinical Trial Management

Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation.

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

Events

.